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Abstract
The titre of virus in a dengue patient and the duration of this viraemia has a profound effect
on whether or not a mosquito will become infected when it feeds on the patient and this, in
turn, is a key driver of the magnitude of a dengue outbreak. The assessment of the hetero-
geneity of viral dynamics in dengue-infected patients and its precise treatment are still
uncertain. Infection onset, patient physiology and immune response are thought to play
major roles in the development of the viral load. Research has explored the interference and
spontaneous generation of defective virus particles, but have not examined both the anti-
body and defective particles during natural infection. We explore the intrinsic variability in
the within-host dynamics of viraemias for a population of patients using the method of popu-
lation of models (POMs). A dataset from 208 patients is used to initially calibrate 20,000
models for the infection kinetics for each of the four dengue virus serotypes. The calibrated
POMs suggests that naturally generated defective particles may interfere with the viraemia,
but the generated defective virus particles are not adequate to reduce high fever and virae-
mia duration. The effect of adding excess defective dengue virus interfering particles to
patients as a therapeutic is evaluated using the calibrated POMs in a bang-bang (on-off or
two-step) optimal control setting. Bang-bang control is a class of binary feedback control
that turns either ‘ON’ or ‘OFF’ at different time points, determined by the system feedback.
Here, the bang-bang control estimates the mathematically optimal dose and duration of the
intervention for each model in the POM set.
Author summary
Dengue virions with deletions or defects in their genomes can be recovered from dengue
patients. These defective viruses can only replicate with the assistance of fully functional
viruses and they reduce the yield of the fully functional viruses. They are known as
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defective interfering (DI) particles. By administering additional, defined, DI particles to
patients it may be possible to reduce the titre and duration of their viraemia. This, in turn
may reduce the severity of the disease and the likelihood that the dengue virus will be
passed from the patient to a mosquito vector. This study estimates the number of DI parti-
cles that would need to be administered, and over what period, to have a significant effect
on patient viraemia and subsequent dengue fever severity.
Introduction
Dengue is caused by four serotypes (1-4) of a virus of the same name [1]. The viruses are trans-
mitted between human hosts by Aedes mosquitoes, most commonly Aedes aegypti. Almost
everyone living between the Tropics of Cancer and Capricorn is at risk of infection and an esti-
mated 300 million infections occur each year [2, 3]. Disease symptoms range from a mild
febrile illness to haemorrhagic fever and hypovolemic shock which, if untreated, is fatal in
about 30% of cases [4]. Mosquito control programs have had little measurable effect on the
number of reported cases of dengue [5], there is no vaccine and no disease specific therapy.
Patients are treated by managing the symptoms with which they present.
Infection with one dengue virus (DENV) serotype probably results in life long immunity
to re-infection with that DENV serotype but a second infection, with a different serotype,
carries a significant risk of developing severe disease [6]. However, the onset of the severe
symptoms in secondary infections usually occurs as the viraemia is waning and the second-
ary immune response is underway [7, 8]. There is a broad correlation between the magnitude
of the viraemia in a dengue patient and the severity of the associated symptoms [9]. Any pro-
cess that reduces the initial viraemia in dengue patients might reduce disease severity and
also the risk that a mosquito feeding on the patient would become infected and pass the virus
to a new host.
Populations of DENV include virions with genomes with defects ranging from single nucle-
otide changes [10] to deletion of more than 90 per cent of the genome [11]. Some of these are
transmitted in nature for a year or more [10]. DENV virions containing genomes with exten-
sive deletions interfere with the replication of wild type viruses. This phenomenon has been
observed with a large number of viruses, mostly with RNA genomes [12, 13]. Furthermore, it
has been possible to demonstrate that virions with defective genomes reduce the yield of virus
from cells infected with wild type DENV and are known, therefore, as defective interfering
(DI) particles [14–16].
There is an extensive literature on the activity of DI particles across a wide range of RNA
viruses but interest waned in the 1990s [13, 17]. With the advent of tools to better define DI
genomes and to produce artificial ones, there has been a renewed interest in their therapeutic
potential and the possibility that they could be used to block transmission of agents such as
DENV. However current mathematical models of dengue [18–20] cannot capture all the
aspects of virus transmission and no model incorporates defective interfering (DI) particles. A
few intracellular, intra-host and population models are available on different infectious dis-
eases such as influenza, scabies, and optimal design for disease control [21–23]. This study
uses data from 208 dengue patients in a clinical setting [8] in order to estimate the therapeutic
potential of DENV DI particles.
We propose a model inspired by the Clapham et. al. [19] and Frank [24] models. The Clap-
ham et. al. is an improved extension of their previous model [20] and focused on two models
of antibody actions against DENV-1 and DENV-2 infections. In model 1, the antibody kills
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infected cells through antibody-dependent cell cytotoxicity (ADCC), and in model 2, the anti-
body assists virus clearance through opsonisation. The authors do not consider the interfer-
ence of DI particles and both models 1 and 2 do not act simultaneously in the same infection
system. The Frank model is a generic model for within-host virus infection kinetics with multi-
ple passages. The main principle of the Frank model is to observe the ‘von Magnus oscillation’
in the virus population, occurring due to the existence of DI particles at multiple passages, sim-
ilar to a ‘predator-pray’ dynamics [25]. The model does not consider any immune response
but classifies the infected cells into several categories according to the order of infection by
virus particles and, or defective particles as early and late infected cells, co-infected cells and
super-infected cells. The Frank model also has a spatial component regulating the density
dependent cell division and virus replication. Our model considers the antibody response in
viral neutralisation and the natural generation of DI particles. As antibody dependent cell cyto-
toxicity (ADCC) is not as likely as virus opsonisation, we do not consider ADCC in the present
model.
In the present paper we propose that we can account for the inherent variability in the
dengue-infected patient data and find a modelling paradigm based on population of models
and optimal control that allows us to quantify the effectiveness of DI particles in controlling
the viraemia. We build an ensemble, population, of models, in which each element in the
population is a mathematical model with exactly the same framework, but where each model
has a different set of parameter values for the same set of parameters. All of these parameter
values are calibrated against multiple biomarker data. A model is selected in the population
of models if its output over a number of febrile days lie in the ranges of the biomarker data.
In particular, we calibrate the data for plasma viral load and antibody response for 208
patients in our POMs. Most of the patients have high viraemia amplitudes during the illness.
However, the antibody data has been collected on two random days within their febrile peri-
ods and that cannot explain the exact dynamics of the antibody response, even asymptoti-
cally. In some cases the biomarker data can have extreme values, but we should not and do
not ignore these values. Our POMs are not constructed with any guaranteed distribution on
the output values of the models. With POMs, we try to explore the range of variability in dif-
ferent cell-virus interactions and the immune responses. There are many different ways of
calibrating the POMs [26–28]. In a previous paper [26] we constructed population of models
in such way that the distribution of the biomarkers matched as well as the distribution in the
data. However, we have based our approach on the first reported [27] that used the range to
calibrate the POM.
We develop a population of controls (POCs) to the population of symptomatic patients to
attenuate the within-host viraemia level and reduce the days of febrile period. Specifically,
bang-bang control is used to determine the minimum dose of DI particles that must be deliv-
ered to minimise the height and duration of the viraemia. Although control theory is mainly
used in engineering, it has become popular in biology recently. Optimal control of disease
treatment, epidemic outbreaks and robust control in protein-protein interaction systems
show notable evidences [29–31]. The dynamical programming of optimal control optimises an
objective function based on the real time status of the system by invoking the control variable
as an external force. Although continuous control has been used in many cases in engineering
and biology, bang-bang control is less popular due to possible computer implementational dif-
ficulties. Bang-bang control simply flips between the lower and upper boundaries of the con-
trol variable as an ‘on-off’ switch depending on the states of the system. It can be viewed as
more clinically relevant than continuous control [30, 32]. Recently, we have proposed optimal
chemotherapy treatment by continuous and bang-bang control for an acute myeloid leukae-
mia (AML) model [33].
DI particles control dengue viraemia
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Materials and methods
Within-host viraemia dynamics
To explain the novelty of the present model, we must assert that the competitive dynamics
of the DI particles with virus is exhibited in the presence of the antibody response. While the
model of Clapham et al. [19] included the role of antibody response in controlling the levels
of viraemia, the model assumed that only standard virus is replicated within the host body.
Defective interfering particles (DI particles) may also be responsible for the reduction in the
production of standard virus [11, 14]. The dynamics of the present model is given by in the fol-
lowing set of ordinary differential equations
dCU
dt
¼ rCU 1  
N
K
� �
  kðV þ DÞCU þ aCD
dCD
dt
¼ kðCUD   CDVÞ   aCD
dCV
dt
¼ kðCUV   CVDÞ   ðp1 þ mÞCV
dCV�
dt
¼ p1CV   dCV�
dCVD
dt
¼ kðCVDþ CDVÞ þ mCV   dCVD
dV
dt
¼ bp2CV�   rV   �ZV
dD
dt
¼ g�CVD   rD   �ZD|{z}
antibody mediated DIP clearance
dZ
dt
¼ Z1Z
V
Z2 þ V
þ Z1Z
D
Z2 þ D|fflfflfflfflfflfflffl{zfflfflfflfflfflfflffl}
DIP particle  triggered immune response
N ¼ CU þ CD þ CV þ CV� þ CVD:
ð1Þ
With very specific aspects of dengue infection from previous models [17, 19, 24], this new
model describes the dynamics of standard virus (V) and DI particles (D) within the host. We
consider the antibody response (Z) by the infected cells in virus neutralisation and DI particle
clearance. The uninfected target cells (CU) become infected and consequently produce four
types of infected cells: infected by DI particles only (CD), virus only (CV), virus-infected and
late enough for further infection (CV�), and infected by both (CVD) (Fig 1).
The assumptions that underpin our new model are described here. Bursting and cell lysis
do not occur during the release of dengue virus particles. Infected cells are categorised in two
classes according to their stages of infection: early and late. The early infected cells (CD and
CV) are available for super-infection, but the late infected cells (CV� and CVD) are not because
of the triggered interferon response and alteration in cell membrane receptor dynamics [34,
35]. Once the infected cells start replicating the virus and, or DI particles, the interferon path-
way is triggered to destroy the uptaken virus genomes inside the cells and also secrets inter-
feron in the immediate neighborhood. The cell surface receptors (toll-like receptors, etc.)
change conformation in the extracellular and cytosolic domains in response to the activation
DI particles control dengue viraemia
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of interferon pathway so that the infecting virus particles cannot dock on the cell surface.
Eventually, the late infected cells (CVD, CV�) die naturally, whereas the early infected cells (CD,
CV) transform into the late infection state before natural death as the rate of infection is much
faster than the rate of infected cell death [24]. As incorporating natural death terms for the
early infected cells cannot contribute significantly to the model output dynamics, we do not
consider them in the present model (See S1 Fig). The immune response is strong in the case of
secondary infection leading to antibody-dependent enhancement (ADE) of the viraemia while
it is very weak in case of primary infection. As the antibody production occurs in a B cell matu-
ration-mediated process, the functional form of the immune response should implicitly take
care of the immune cell proliferation [36]. We consider the immune response in a simplified
Hill-type function without any cooperativity so that the response is prominent only in the
presence of significant antibody level, preferably in case of secondary infection. Both the defec-
tive and standard virus particles in this model are equally efficient in the competition of infec-
tion or replication and respond in similar way to the antibody, as we do not consider the
nucleotide length dependent intracellular replication or packaging kinetics here. Rather, we
consider detailed replication and packaging mechanisms in a separate article, where a single
cell model explains the replication dependent on nucleotide-length, RNA secondary structure,
and diffusion-mediated queuing for RNA encapsidation.
Most of the model parameters must be estimated from the reported base values as the
model is quite different from previous models, although the range of their values from the
aforesaid papers [19, 24] are informative in creating the population of models. The initial con-
ditions of CU, CD, CV, CV�, CVD and D are considered constant at the start of infection. Only
the initial viral load (V0) and antibody levels (Z0) for each patient have been sampled in the
population of models. The patient-specific parameters (α, δ, η1, η2, π1, π2, ϕ) are sampled using
Latin Hypercube sampling (LHS) within the physiological range. LHS is a way of sampling
high dimensional parameter spaces so that the number of samples does not scale with the
Fig 1. Schematic diagram of the within-host dengue virus infection dynamics. The uninfected target cells (CU) can
be infected by either virus particles (V), or defective particles (D) to generate early infected CV and CD cells. The CD
cells can either be transformed into CVD cells by super-infection, or come back to uninfected state (CU) by losing the
DI particles. CV cells can also be transformed into CVD cells either being infected by DI particles or through mutation
of the virus genomes inside it. Otherwise, CV cells mature to late infected CV� cells. The CVD and CV� cells are able to
replicate and release the defective particles and the standard dengue virus, respectively. The occurrence of viral
particles of any kind (V and/or D) in the blood plasma triggers the antibody response (Z), which in turn prevents the
infected cells (CVD and CV�) at virus production. The cell death has been considered only for CVD and CV� infected cells
as the other two infected cells (CD and CV) transform themselves quickly into other states.
https://doi.org/10.1371/journal.pcbi.1006668.g001
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dimension [37]. The way this is done is to discretise a d dimensional parameter space with
some mesh and then place a cross in a box such that there is only ever one cross in each d − 1
dimensional subspace. A cross means that box is sampled at random for the d parameter val-
ues. The remaining parameters have been classified into two classes: natural human host
parameters (r and K), which are constant in the complete set of POMs, and serotype-specific
parameters (β, �, γ, k, μ, ρ), which stay constant for a POMs of a particular serotype. We tabu-
late the description of the rate parameters in Table 1.
Population of models
Variability inherently occurs in many biological and physiological measurements and we can-
not avoid them. Every patient, for example, may have very different responses to an infection
or a treatment and we need to account for this variability. Sometimes we aggregate the data
and fit the model to the mean trajectory or choose a subset of the data as being representative
or the hypothetically best sets of data and extrapolate those features to the large population.
This can reduce the errors in measurement, but is unable to capture the intrinsic variability in
the system. Hence, analysing models in a population from a set of measured data and explor-
ing the hidden features intrinsic to the system is more effective for predicting physiological
phenomena when there is inherent variability.
As our model is based on a consolidation of two different models, an initial estimation of
the model parameters is essential. We use ‘arFitLHS’ tool of ‘Data2Dynamics’ package in
Matlab for initial parameter estimation for the base model [38]. For this parameter estimation,
we use the median of the viraemia and antibody response data for each serotype. We generate
multiple candidate models with parameters sampled by Latin Hypercube Sampling. We are
at liberty to choose different criteria for our calibration. Previous work has calibrated to the
Table 1. Kinetic rate parameters and their sampling ranges used in the POMs.
Parameters Values Descriptions Source
Natural human host parameters
K 3.505 ×107 cells per ml Cellular carrying capacity of proliferation [24]
r 15.217 per day Intrinsic rate of host cell proliferation [24]
CU0 1.0 ×108 per ml Level of uninfected target cells on the day 0 of illness -
Serotype-specific parameters
β 758.045 Number of V released per CV� cells after packaging [24]
� 16.225 per day Antibody-mediated virus neutralisation [19]
γ 38.259 Number of D released per CVD cells after packaging [24]
k 2.45 ×10−10 per day Rate of infection per virus [19]
μ 37.651 per day Mutation rate of V to D within host cells, turning CV cells into CVD cells [24]
ρ 9.562 per day Natural clearance rate of V and D [19]
Patient-specific parameters
α 5.836 ×10±2 per day Rate of loss of DI particles within host cells, turning CD cells into CU cells [24]
δ 2.426 ×10±2 per day Death rate of infected cells [19]
η1 1.607 ×10±2 per day Proliferation rate of triggered immune response per infected cells by V or D [19]
η2 2.0 ×108±2 Threshold parameter of the triggered immune cells proliferation [19]
π1 9.863 ×10±2 per day Rate of maturation of CV cells into CV� cells [24]
π2 68.503 ×10±2 per day Rate at which each CV� cells produces V [24]
ϕ 21.782 ×10±2 per day Rate at which each CVD cells produces D [24]
V0 3.6 ×105±2 per ml viraemia level on the day 0 of illness -
Z0 5.645 ×10−2±2 per ml Level of immune response on the day 0 of illness -
https://doi.org/10.1371/journal.pcbi.1006668.t001
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ranges of the data [28], but this is somewhat crude. More recently, we proposed calibration
based on matching the distributions in the data available [26]. This means that appropriate
outputs from the POM matches the data in a distribution setting. In the present article we
are following the earlier approach. First, Latin Hypercube sampling is performed to generate
20,000 parameter sets for 7 patient-specific parameters (α, δ, η1, η2, π1, π2, ϕ) and initial condi-
tions of virus (V0) and antibody response (Z0) with the serotype-specific parameters (β, �, γ, k,
μ, ρ) constant for each serotype, simultaneously. We keep the natural human host parameters
(r and K) same for the four serotypes. The parameter sets generated in LHS are used to simu-
late 20,000 variants of the same model. Hence, we generate a very large initial population of
models (20,000) for each serotype. The model calibration is the next step that decides whether
a model should be included or not in the final POMs. We use upper and lower values of the
available biomarker data on each day of illness as the allowed range of acceptance for the
model output variability. We select only those models that cover the range for the biomarker
results on each day of illness. This calibrated population possesses all plausible models with
dynamic variability within the data range.
Optimal bang-bang control
The aim of optimal control is to determine the temporal profile of a control variable that opti-
mises a defined objective function. The objective function, or the payoff, is structured from the
state and control variables along the time trajectory and/or at the final time. There are two
ways of implementing optimal control. One is continuous and differentiable. The other one is
continuous but occurs as a step function and is known as bang-bang control, in which the con-
trol is either on or off. In practical settings bang-bang control is more appropriate for interven-
tion and that is what we use here.
We follow the algorithmic steps for optimal control for a nonlinear system of ODEs as
follows
1. Describe the system with the control variable (u) and initial state, x(0) = x0 as
dx
dt
¼ Aðx; tÞx þ Bðx; tÞuþ C: ð2Þ
The final time Tf and final state x(Tf) should be specified as free or fixed according to the
context of the problem. In the present model, we use fixed final time Tf and free final state
x(Tf).
2. Construct the payoff functional in terms of running cost (L) and terminal cost (ϕ) func-
tional as
min
u�½0;ub�
Jð:Þ≔ �ðxðTf Þ;Tf Þ þ
Z Tf
T0
Lðx;u; tÞdt
 !
; ð3Þ
where u is the control variable, or vector of control variables, with bounds 0� u� ub. By
choosing an optimal control u�(t) and solving the state x(t), one can find the optimal payoff.
The optimal control can be determined by solving the necessary conditions through Pon-
tryagin’s minimum principal (PMP) [39, 40].
3. Construct the Hamiltonian following PMP for an unconstrained problem
H ¼ lTðAðx; tÞxþ Bðx; tÞuþ CÞ þ Lðx; u; tÞ: ð4Þ
DI particles control dengue viraemia
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For bang-bang control, L(x, u, t) can be written in a linear form as L1(x, t)x + L2(x, t)u + L3
and the Hamiltonian must be rewritten in the form
H ¼ lTðA1ðx; tÞx þ B1ðx; tÞuþ C1Þ; ð5Þ
where, A1 = A + (1/λ)L1(x, t), B1 = B + (1/λ)L2(x, t) and C1 = C + (1/λ)L3. Here the lambda
are the elements of the vector of Lagrange multipliers or the adjoint variables for an uncon-
strained control problem. Negative partial differential of the Hamiltonian with respect to
each state variable (xi, i = 1, 2, . . .) generates corresponding costate equation, which is the
time derivative of the adjoint variable (λi, i = 1, 2, . . .) as
@li
@t
¼  
@H
@xi
: ð6Þ
In the present model, we have eight costate equations corresponding to eight state equa-
tions (Eq 1).
4. From the Pontryagin’s minimum principal, the switching function for a bang-bang control
is
@H
@u
¼ l
TB1ðx; tÞ: ð7Þ
The values of the switching function can be positive or negative. A zero value of the switch-
ing function represents singular control. The particular time points, where the switching
function changes sign are known as the switching points and the duration between the
switches are called the bang times (τ’s). After every bang time (τ1, τ2,‥), the bang-bang con-
trol variable turns on or off depending on the direction of switching.
5. The optimal bang-bang control (u�(t)) flips between the bounds, [0, ub] at the switching
points as
u�ðtÞ ¼   signðlTB1ðx; tÞÞub: ð8Þ
In the present study we use one control variable (u(t)), the administration of excess DI par-
ticles to the model to reduce the viral infection as well as quick clearance of the virus from
the host. For the present POMs of four dengue serotypes, the range of the viraemia growth
is large (approximately 103 to 1011). For that reason it is difficult to decide on upper bounds
of the control (ub) for these POMs. We determine the ub from the individual uncontrolled
viraemia profile for each model considered to be controlled.
In dynamical programming of bang-bang control for linear systems, the control can be
computed numerically using boundary value problem (BVP) solvers [41]. But a nonlinear
two-point boundary value problem (TPBVP), such as our present model, cannot be solved
directly with traditional numerical boundary value problem solvers. We use the forward-back-
ward sweep method, where ordinary differential equations solvers are used twice: forwards
for the state equations and backwards for the costate equations [42]. Then we update the
switching function(@H/@u) and the control (u(t)) [30, 43]. We use Pontryagin’s minimum
principle and solve the discontinuous right hand side of the state and co-state equations. We
note that this method needs many more iterations than continuous control methods to con-
verge. However, for models with strong non-linearity such as stiff and oscillatory control prob-
lems, this approach is reasonably efficient.
Control strategy for dengue fever. As our aim is to control dengue within host, we con-
struct an objective function in terms of the running cost functional only and do not include a
DI particles control dengue viraemia
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terminal cost (see Eq 3). The reason for this is that the infection and virus are naturally cleared
at the final time point and so terminal cost functional is insignificant in such cases. Thus we
take
min
u�½0;ub�
Jð:Þ≔
Z Tf
T0
1
2
aV2ðtÞ þ
1
2
bC2VðtÞ þ cuðtÞ
� �
dt
 !
; ð9Þ
where T0 and Tf are the initial and final time, and a, b and c are constants to be determined
from the optimal control problem. Note that the squared terms (1
2
V2ðtÞ and 1
2
C2VðtÞ) act like an
energy in the system (a Hamiltonian) while the linear term in the control implies that we use
bang-bang (on-off) control rather than a continuous control. We assume equal weighting on
the three terms, so a = b = c = 1. In the course of dengue control, we prefer to apply a bang-
bang control rather than a continuous control. Here, the administration dose rate (u(t)) of DI
particles is the control variable. The medical nomenclature of the purified DI particles is thera-
peutic interfering particles or TIPs. In order to make the vaccination program cost-effective
and reduce the time course of the vaccination process this information is included in the struc-
ture of the payoff function during the optimisation. As the plasma viraemia (V) and the cellular
infection of all kinds (CV, CV�) show a rapid growth in the first 2-4 days of the febrile period
and are cleared within 10-12 days, we seek to minimise the peak of the viraemia (V) and virus-
infected cells (CV) that in consequence may help reduce all the infections. The DI particles
within the host (D) compete with the virus for the uninfected cells (CU) and that is an advan-
tage to introduce a large number of DI particles to inhibit the viral infection. The system of
ordinary differential equations (Eq 1) can be rewritten after introducing the control variable, u
(t) as
dCU
dt
¼ rCUð1  
N
K
Þ   kðV þ DÞCU þ aCD
dCD
dt
¼ kðCUD   CDVÞ   aCD
dCV
dt
¼ kðCUV   CVDÞ   ðp1 þ mÞCV
dCV�
dt
¼ p1CV   dCV�
dCVD
dt
¼ kðCVDþ CDVÞ þ mCV   dCVD
dV
dt
¼ bp2CV�   ðrþ �ZÞV
dD
dt
¼ uðtÞ þ g�CVD   ðrþ �ZÞD
dZ
dt
¼ Z1Zð
V
ðZ2 þ VÞ
þ
D
ðZ2 þ DÞ
Þ
N ¼ CU þ CD þ CV þ CV� þ CVD:
ð10Þ
We assign bang-bang controls to the models from the POMs discussed above and obtain a
population of controls (POCs) defined by the vectors of the amplitude of the bang of DI
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administration dose (u(t)) and on-off time duration (τ’s) of the bang-bang switches for each of
the four serotypes.
Results
Our main assumption for this study is that we can leverage existing data sets and mature mod-
els to explore the underlying heterogeneity implicit in the data and the processes that are being
analysed. We do this using population of models (POMs) of within-host virus dynamics for
each of the four dengue serotypes. We generate an initial database of 20,000 candidate models
with the parameters chosen through Latin Hypercube Sampling and select only those models
for the POMs that generate outputs that lie within the biomarker data range. The effect of
virus infection on host innate immunity is recognised indirectly by immune cell proliferation
and antibody production. Once the POMs have been calibrated, excess DI particles are used
via optimal bang-bang control to inhibit the within-host viral burden and reduce the fever
duration.
Population of models
From the clinical data, we have a set of 208 adult dengue patients with more than 3 days of
fever [8]. Among them, 38% and 40% of cases are DENV-1 and DENV-2 infections and a very
low number of cases from DENV-3 (12%) and DENV-4 (11%). Most of the patients enrolled
into hospital on days 2, 3 and 4 of their illness with high viraemia load in their blood samples.
To build a model with an estimate of the day of infection using the day of illness is not appro-
priate. The days between the infection and start of illness are known as the incubation period
for the plasma viraemia. For a large population of patients, it is difficult to frame the range of
this time period in a dynamical model. To address this problem, we consider that the start of
illness is a day in between the day of infection and maximum plasma viral load. The fever starts
with a range of detectable viraemia load (V0) on the day the illness starts. Although DI particles
are not observed directly in any prior study of blood viraemia trajectories, they are known to
occur naturally in viral infection systems. We may predict that effect from our POMs con-
struction, since they are generated naturally in viral infection systems. Fig 2 represents the cali-
brated POMs (black transparent lines) with the reported plasma viraemia (red lines with dots)
for each of the four DENV serotypes for 10 days of their febrile periods. In the initial calibrated
POMs, we found many viraemia models with large oscillations and abrupt growth in the anti-
body models. Although they satisfy the calibration criteria to be included in the final POMs,
they are omitted from the analysis as we cannot find any oscillatory behaviour in the reported
viraemia data.
In Fig 2, we present the POMs constructed (black transparent lines) based on the available
biomarker data (red lines with dots). The data for the viraemia are regularly collected for every
patients from day 2 to day 8 and that is reflected in the calibrated POMs nicely. But the avail-
able data for the antibody response is not as consistent as they appear randomly on any two of
the days of illness. Calibration of the POMs for these data does not perform as effectively as for
the viraemia population. To analyse the POMs for the four serotypes comparatively, we see
that the POMs for DENV-2 is the most tightly calibrated with the biomarker data. The POMs
for DENV-1 and DENV-4 are well calibrated in the dense region of the data and very few out-
lying data points cannot be captured in the POMs while DENV-3 POMs captures the spread
of the data at every day of illness. In the case of DENV-2 and DENV-3, the recurrence of tiny
oscillations near the peaks of their rapid growths in the viraemia are more prominent than in
DENV-1 and DENV-4 although that does not affect the antibody response. The antibody
dynamics for the four serotypes are quite similar except in DENV-4. It is quite low in
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comparison to the other serotypes. The coverage of the data spread by the calibrated POMs
and the goodness of the calibration is presented by scattered plots in Fig 3.
In Fig 3, we depict the antibody response with respect to corresponding viraemia levels on
every day of illness for further clarification of the calibration process. The black dots are the
antibody-viraemia data points calculated from the accepted POMs on each day of illness. We
show that most of the POMs results stay within the ranges (red boxes) of the biomarker data
on day 3, 4, 5 and 6 for all the four serotypes. On days 2, 7 and 8, due to very low number of
data-points, the range of detection is not a reliable indicator of goodness of fit for the POMs. If
we look at the day-wise calibration of each serotype, the best calibration is observed in case of
DENV-1. On days 2 and 8 for DENV-2, there is no available scope for calibration because only
a single data point is available for antibody response. A similar situation is observed on days 7
and 8 for DENV-3 and DENV-4.
The spreads in different patient-specific parameters for the four serotypes are shown in par-
allel coordinate planner graphs in Fig 4. We consider 7 patient-specific parameters (α, δ, η1, η2,
ϕ, π1, π2) and initial conditions of virus (V0) and antibody response (Z0) as the y-axes of the
9-dimensional parallel coordinates. The rate of triggered immune response proliferation (η1)
has notable differences in the case of DENV-4 from the other three serotypes. The effect of this
narrow spread in η1 is reflected in the POMs for the DENV-4 antibody response in Fig 2B.
The initial viraemia level (V0) spreads in a narrow domain for DENV-4 compared with the
others and it makes the viraemia POMs in Fig 2A narrow. DENV-3, with its very narrow
spread in V0, appears to be wide in the course of time. In all the cases, the low value of η2, the
threshold of immune response proliferation, is inversely related to high level of V0.
For each of the patient-specific parameters, which have been allowed to vary in the popula-
tion, the partial correlation coefficient (PCC) is calculated pairwise with the viraemia (V),
defective particles (D) and antibody response (Z), calculated from the POMs. This correlation
based approach can explore the sensitivity of the model parameters in association with the
parameter variability. PCC is a parametric measure of sensitivity analysis that detects the
Fig 2. Population of models. The data of (A) viraemia and (B) antibody response for 208 (78 for DENV-1, 83 for DENV-2, 25 for DENV-3 and
22 for DENV-4) hospitalised dengue patients reported in Nguyen et al [8] are calibrated to construct serotype specific population of models
(POMs). The biomarker data are shown in red lines with dots and the calibrated models from the POMs are plotted in transparent black lines.
The calibration is performed for the ranges of available data on each day of illness. The total number of calibrated models in the POMs is 701
(221 for DENV-1, 306 for DENV-2, 93 for DENV-3 and 81 for DENV-4). The level of viraemia on day zero of illness is covered with the
heterogeneity generated by the viral load on the day of infection and the incubation period.
https://doi.org/10.1371/journal.pcbi.1006668.g002
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degree of association between output and input variables of a dynamic model by removing
the existing correlations of the other model variables with these two variables [46, 47]. To cal-
culate PCC for a set of multiple variables, one has to compute the co-factor matrix (C) of the
Pearson’s correlation matrix for the variables. The PCC of a pair of variables is defined as
  Cij=
ffiffiffiffiffiffiffiffiffi
CiiCjj
q
. Here, PCC identifies one-to-one correlation between a particular model parame-
ter with the specific model output after removing the contributions of all the other model com-
ponents. Thus it magnifies the one-to-one correlation between the parameter-output pairs. In
Fig 5, we present three different heatmaps to quantitatively compare the PCC levels among the
patient-specific parameters and the viraemia load, antibody response and accumulated DI par-
ticles levels across the four serotypes. Interestingly, although the POMs for viraemia load and
antibody response show similar trends, the relation is not just straightforward if we look at the
contributions of the model parameters through their PCC values.
In row Fig 5A, the PCCs of viraemia with different parameters are plotted. The death rate
of infected cells (δ) shows a transition from highly positive to highly negative correlation as
long as the illness continues, while the proliferation rate of the triggered immune response (η1)
moves in the opposite direction. However, the threshold parameter of the immune response
(η2) is not following a similar trend across the serotypes. To classify the PCCs for η2, DENV-1
and DENV-3 are separable from the class of DENV-2 and DENV-4. On the other hand, the
rate of DI particle loss (α) from CD cells and production (ϕ) by CVD cells, the rate of CV cells
maturation (π1) and virus release (π2), initial condition of viraemia (V0) and antibody response
(Z0) remain almost in the weak correlation regime with the viraemia for all the serotypes. In
Fig 3. Calibration of the population of models. The scattered plots of antibody response vs. viraemia calculated from the calibrated POMs are
shown on each day of illness. Each row represents a serotype as (A) DENV-1, (B)DENV-2, (C) DENV-3 and (D) DENV-4. The red boxes in all
plots represent the range of the biomarker levels in the dataset on the particular day of illness. Every scattered plot represents the compact
calibration of the models with available bimarker data. We do not show days 1, 9 and 10 as there is no available data for these days. The
calibration of DENV-2, DENV-3 and DENV-4 POMs are weakly calibrated on day 2, 7, and 8 due to lack of availability of data. Day 2 and day 8
in the DENV-2 POMs, and day 8 in the DENV-3 POMs do not have any antibody data. In the DENV-4 POMs, day 7 and day 8 have single
observations for viraemia and no antibody response data is recorded.
https://doi.org/10.1371/journal.pcbi.1006668.g003
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row Fig 5B, the PCCs of the antibody response with δ show high negative correlation while the
rest of the parameters have no significant contributions. In the case of DI particles in row Fig
5C, all the parameters except the production rates for DI (ϕ) and virus (π2) appear with the
same trend in Fig 5A, while ϕ and π2 show high positive correlation in all the serotypes on
nearly every day of illness.
Efficacy of DI particle-mediated treatment
Administration of excess DI particles into the DENV-infected host system must have an effect
but its efficacy is highly dependent on the day of intervention and the dose of treatment. To
observe these two points, we consider a model arbitrarily chosen from the sets of POMs and
consider two different strategies: single-time doses of increasing strengths are applied on dif-
ferent days of illness, and bang-bang optimal control is performed for increasing doses that
producing optimum payoff values.
In the first experiment, we observe twelve study sets with three different doses of excess DI
particles added on four different days of illness during the increase of the viral load such as,
day 0, day 1, day 2 and day 3. Therefore, each study is observed for the entire duration of the
fever with a single dose of excess DIPs added on a particular day. Here, we want to mention
that in all the models in the four POMs, the initial values of DI particles are kept zero assuming
Fig 4. Variability in model parameters. The patient-specific parameters are shown in parallel co-ordinates for the four calibrated POMs of (A)
DENV-1, (B) DENV-2, (C) DENV-3 and (D) DENV-4. These parameters values represent the models included in the four serotype-specific
POMs. The parameters have been sampled for 20,000 models using Latin Hypercube Sampling from a domain of 10−2 to 102 times the initial
parameter values and parameter sets for the qualified models included in the parallel co-ordinates. If we draw multiple copies of the y-axis,
perpendicular to the x-axis and equidistant with each other, then these represent the axes of the multi-dimensional parallel coordinates for a
high dimensional Euclidean system [44, 45]. Any data point in a multi-dimensional space can be mapped on a polyline that connects each axis
of the parallel coordinates at a distance proportional to its coordinate value.
https://doi.org/10.1371/journal.pcbi.1006668.g004
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that without any viral infection, DI particles production is not possible. In Fig 6, we present
the viraemia and DI particles dynamics for the model. We can observe that a treatment of a
very high dose (1010) of DI addition before the fever starts, i.e, on day 0, can effectively reduce
the viraemia, but it is futile if added after the fever starts. Other lower doses (108 − 109) remain
Fig 5. Partial correlation coefficient heatmaps. The partial correlation coefficients are calculated between the patient-specific
parameter (α, δ, η1, η2, V0, Z0, ϕ, π1, π2) values and the model outputs (A) viraemia, (B) antibody response and (C) defective
particles, respectively in the calibrated POMs. The correlation heatmaps are shown on each day of illness (2-8). The red and blue
colours represent negative and positive correlations, respectively while white colour stands for weak or no correlation.
https://doi.org/10.1371/journal.pcbi.1006668.g005
Fig 6. Single time point DI particles (DIP) treatment. Different doses of excess DI particles are added to a within-
host dengue viral infection model at different single time points. The effect of the treatment are shown by the dynamics
of (A) viraemia and (B) DI particles. The blue lines represent the trajectories of virus and DI particles without applying
the treatment of adding DI particles. The lines in red, yellow and purple are the corresponding virus and DI particles
dynamics with the addition of 108, 109 and 1010 copies of DI particles, respectively on 0, 1, 2 and 3 days of illness.
Although a very high dose (1010) of DI treatment on day 0 of the illness can reduce the treated viraemia peak by
approximately 100 fold and also the duration of illness, the same dose becomes less effective if applied on days 1, 2 and
3 of illness. The other doses of 108 and 109 do not show notable efficiency, even if applied on day 0.
https://doi.org/10.1371/journal.pcbi.1006668.g006
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impractical even if they are added on day 0. One might ask why anyone would go for a treat-
ment unless any dengue symptom is observed. This question is answered with the application
of optimal bang-bang control treatment of DI particle addition instead of a single time point
treatment.
In Fig 7 we observe the second experiment, where a course of intervention strategy during
early days of illness is successful in reducing the viraemia peak and the duration of virus clear-
ance. In this context it is important to note that increasing the dose strength of DI addition
makes the duration of the treatment shorter and the virus is also cleared earlier. However, in
terms of the expense of this control treatment (measured by the area under the control curve)
with respect to the decrease in viraemia, this may not be optimal. We will discuss on this point
later with multiple models from each of the serotype-specific POMs.
Population of controls
Once the POMs have been constructed, we approach the problem of predicting the treat-
ment for controlling the fever in the virtual population of dengue patient models. As the
total number of calibrated models in the POMs is large (221 for DENV-1, 306 for DENV-2,
93 for DENV-3, and 81 for DENV-4), we randomly choose 15% of the candidate models
from each serotype-specific POMs for the control experiment. We sample the models from
the POMs with a uniform distribution and obtain 33, 45, 13 and 12 models for DENV-1,
DENV-2, DENV-3 and DENV-4, respectively. We could have chosen the best 15% of the
best fitted models as the candidates for control experiment, but those do not appear in every
domain of the POMs. In Fig 8, we present the viraemia, and DI particle levels before and
after applying the control. For DENV-1, the viraemia lasts until day 10 keeping the control
on for the whole period in most of the cases, while in case of the other serotypes the control
shuts down approximately by day 8. The occurrence of the oscillatory peak in some DENV-
2 and DENV-3 models, pushes the control to higher dose although the viraemia cannot last
beyond day 5.
If we consider the area under the control curve as the control expense (A), then an efficient
control must be cost effective. To test the efficiency of the control, we estimate the area under
the curve of the viraemia fold reduction (R) with respect to the area under the prescribed dose
Fig 7. Optimisation of the dose treatment. A very high dose of DI particles treatment can reduce the viraemia peak
and clears the viral load within fewer days, but it may not lead to optimal control treatment in terms of the objective
function and the expense of the control. For an arbitrary model from the sets of POMs, we observe the effect of
different doses (control upper bound) of DI particles addition and solving for the switching time point. The black lines
are the trajectories of uncontrolled viraemia and DI particles. The coloured lines are the controlled trajectories of the
viraemia and DI particles and the control profiles with different control upper bounds of 1.0 × 109 (red), 2.0 × 109
(blue), and 4.0 × 109 (green) copies of DI particles. We have estimated the efficiency of the control treatment in terms
of viraemia reduction later.
https://doi.org/10.1371/journal.pcbi.1006668.g007
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Fig 8. Effect of control treatment on viraemia and defective particles. Representatives of each serotype-specific infected POMs are considered
for bang-bang control treatment with addition of excess DI particles as therapeutics. The black lines in the viraemia and DI particles columns
are the untreated models from the POMs of (A) DENV-1, (B) DENV-2, (C) DENV-3 and (D) DENV-4, respectively. The coloured lines in the
viraemia, DI particles and the control columns show the same models after the treatment with excess DI particles. The colours are used to
observe a treated viraemia profile with corresponding treated profile of DI particles and control treatment. Each POMs appears with notable
reduction in the viraemia profiles after successful addition of optimal doses of DI particles for optimal time periods.
https://doi.org/10.1371/journal.pcbi.1006668.g008
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of control curve (A). Here the fold reduction (R) and control expense (A) are defined as
R ¼
R T
0
VðtÞ
ðbefore controlÞdt
R T
0
VðtÞ
ðafter controlÞdt
; ð11Þ
A ¼
Z T
0
uðtÞdt;T ¼ 10 days: ð12Þ
In Fig 9, we show the distribution of the viraemia fold reduction with respect to the control
expense for all the four serotypes. Approximate monotonic increments are observed in R, with
A for all the serotypes except DENV-2. For DENV-2, we find two separable clusters; one lies in
the same cluster as the other serotypes and the other cluster appears with a completely opposite
trend but at higher control expense.
The infected cellular dynamics also shows remarkable changes after the application of
excess DI particles in the host system (Fig 10). The general trend before and after applying the
control is observed in the CD cells, which is similar to that of the DI particles, as the DI particles
are the major reason to generate the pool of CD cells. A similar relation is observed between
the CV� cells with the viraemia profile as only CV� cells release potential virus into the body
Fig 9. Control efficiency. The efficiency of the intervention strategy using bang-bang control is evaluated here. The control expense (A), which
is the area under the control (u(t)) curve, represent the expense of the treatment for the corresponding patients, who responded with a (R) fold
reduction in their corresponding viraemia peak. The (R) fold reduction in the viraemia peak is plotted with respect to the normalised control
expense (A) for the four serotypes, DENV-1 (red), DENV-2 (blue), DENV-3 (green), DENV-4 (cyan).
https://doi.org/10.1371/journal.pcbi.1006668.g009
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fluid. Interestingly, the application of the excess DI particles starts inhibiting both the virus
and the CV� cells. The population of CD cells are produced from CU cells upon being infected
by D and CVD cells produce D. As a result, the pool of the DI particles drops sharply as soon as
the control shuts down and the consequences are reflected in the numbers of CD and CVD cells.
Discussion
The two prime interests of this paper are to capture the inherent variability in dengue-infected
patient data through a within-host model and predict efficient intervention to control dengue
fever via administration of excess defective interfering particles (DI particles). We present the
method of population of models (POMs) to execute the first goal and a population of optimal
bang-bang control settings for the second aim. We show that the POMs not only capture the
biomarker dataset but also provides the range of variability for each cell-virus interaction and
its association with the biomarker kinetics in population and individual levels. A sub-popula-
tion of the calibrated POMs are used with bang-bang control to reduce the viraemias in signifi-
cant orders. In that case, the fever cannot reach the state of severe dengue and the DI particles
do not stop replicating. As per our findings, the antiviral property of the DI particles appears
as a potential intervention strategy to attenuate the patient viraemia significantly.
We construct four serotype-specific populations of within-host models for dengue against
the variability in the biomarker levels in blood samples of the admitted patients as reported
[8]. The four sets of POMs explore a range of patient-specific parameters, those in different
combinations, produce four populations of feasible dengue models within the range of the
Fig 10. Effect of control treatment on infected cellular dynamics. The dynamics of different cell types are plotted for the candidate models
from four serotypes-specific POMs, which are engaged in the control experiment. The uninfected cells (CU) (black), cells infected by DI particles
only (CD) (blue) and cells late infected by virus (CV�) (red) are shown (A) with and (B) without administration of excess DI particles. The CD
cells are cleared from the system after the treatment is over as they cannot replicate DI particles. The control treatment affects the peaks of CV�
cells as we can see from the rows (A) and (B). The uninfected cell population is not affected greatly with respect to the infected cells population.
https://doi.org/10.1371/journal.pcbi.1006668.g010
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experimental data. The calibration of the POMs helps us to discriminate and classify among
the serotypes and inter-patient variability through parameter variability and sensitivity. The
aim of this methodology is not to look at the dynamics of isolated models in the population as
any single model does not represent an individual. The aim is to incorporate variability in the
same model and observe the whole population of patients with similar symptoms.
Variability appears in the population of the viraemia load and the corresponding antibody
response due to the differences in the patient-specific parameters. One of the crucial factors
that drives this variability is the incubation period for an individual model. We want to men-
tion that we trace the variability of incubation periods of an individual model in terms of the
variability in viral load on day 0 of illness (V0) and that efficiently fits with the calibration pro-
cess. The dynamics of the viraemia (V) is directly dependent on the rate of infected cell death
(δ), maturation rate of CV cells (π1), rate of virus production (π2) for release after maturation
of the infected CV to CV� and on the antibody response (Z) for clearance. Indirectly, the rate of
infection (k) also drives the viraemia. Amongst these parameters, δ is in strong positive corre-
lation with V, Z and D and that gradually leads to a flip as the viraemia dies with the days of ill-
ness, but π1 is weakly correlated all the time. The variability of highly correlated parameters
stay within a narrow range and calibrate tightly with the biomarker data, but weakly correlated
parameters spread over wide ranges to generate models with similar behavior (Figs 4 and 5).
Quantitatively, the strength of correlation of the parameters with the clinical biomarker data is
an estimate of the sensitivity of the model parameters onto the serotype-specific POMs. Here,
variability in the highly sensitive mature infected cell (CV�) death rate (δ) has a more significant
role than the comparatively lower sensitive maturation rate (π1) of CV cells in the variability of
the virus clearance and duration of dengue fever. The dynamics of CV� in Eq 1 informs the pos-
sible structure of the objective function for an efficient optimal control based on the compara-
tive parameter sensitivity. In the present optimisation problem, we minimise the early infected
cells (CV) with the plasma viral load (V), not the late infected cells (CV�) (see Eq 9).
In the Ben-Shachar et. al. [48] statistical model, the populations of infected patients have
been classified according to the disease severity across the serotypes and the variability in their
immune responses. Although this study is more concerned with the immune response, they
predicted the relation among virus replication rates with the timing of the viraemia peaks over
the days of illness. Our POMs results show consistency with their observations when we dem-
onstrate the variability for different parameters. DENV-1 and DENV-4 reach the viraemia
peaks after the symptom onset, while the peaks appear before the onset of the symptoms in
case of DENV-2 and DENV-3 and it depends on the degree of infection (Fig 2). However,
the few relatively high peak heights in viraemia data for DENV-1 cannot be captured in our
model.
Among the reported infections of the hospitalised patients in our model, most of the
DENV-1 infected patients have primary infection while the majority of the patients with the
other serotypes are reported as secondary infection. A careful observation of the POMs of the
viraemia profiles enables us to find the growth rate of the viraemia for most of the models,
with the DENV-2 and DENV-3 POMs growing faster than the others. We explain this rapid
growth in terms of the antibody dependent enhancement (ADE) that only occurs in secondary
infection [6]. In case of primary infection, the immune response is triggered very slowly and
the viraemia is almost cleared when the response level is significant. On the other hand, the
same response for the secondary infection is very rapid and prominent.
In the articles of Clapham et. al., two different within-host models for dengue infection
have been presented for DENV-1 and DENV-2. These authors studied variability in the rate of
infection (k) only and that was used to discriminate between the ranges of viraemia loads [20].
Later they have calibrated two improved models with direct and indirect effects of the antibody
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response through free virus neutralisation and infected cell death [19]. In the present article,
we keep the rate of infection (k) and rate of antibody-mediated virus neutralisation (�) con-
stant for each serotype and included the immune cell-mediated antibody production, which is
triggered by both the free virus and free defective particles. The variability in the antibody pro-
duction is captured by η1 and η2 and their contributions are reflected in the construction of
the POMs. The greater the proliferation (η1) rate varies, the more the antibody plateau widens
(Figs 2 and 4). Notably, in the case of DENV-4, the spread for both of η1 and η2 are narrow.
The strong negative correlation of η1 with the viraemia does not appear to be significant in
comparison with the case of the DI particles and immune response. This may explain the delay
in the triggered antibody response generated by D. In principle, the antibody response is acti-
vated after the virus population (standard or defective) has reached its peak and the production
of DI particles is marginally delayed. This observation suggests a cue to investigate the different
time-scales of the virus proliferation and activation of the immune response.
Another significant outcome of such a population level modeling approach is in the evalua-
tion of the dose and duration of an intervention strategy for dengue fever. We use a bang-bang
control approach to model adding excess DI particles into the dengue-infected host system in
order to reduce the plasma viral burden and the fever. Note that the optimal control gives an
optimal dose in a mathematical setting. Of course this may not be optimal in a real life setting
due to other factors that are beyond the scope of the model to represent. This of course is
always the case when modelling is done. Previously, Rodrigues et. al. showed optimal control
for dengue using vaccination compartment inside an epidemic viewpoint [18]. But intervening
individual human host models within a population has not been observed yet. Furthermore,
the naturally occurring defective interfering particles have not been utilised in dengue control
before.
We perform the control experiment on a randomly chosen 15 per cent of models from the
calibrated population of models for each serotype. In Fig 8, the population of controlled mod-
els (cPOMs) and population of controls (POCs) profiles for the four serotypes are presented
with the uncontrolled POMs. As the replication of the DI genomes depends on the replicative
machinery synthesised by the standard viral genomes, the excess DI particles are rapidly
cleared out of the host system as soon as the control shuts down and viraemia is cleared. We
ensure the amplitude of the control, i.e., addition of excess DI particles, to be equivalent to the
level of viraemia peak during the controls, otherwise the amount of the DI particles are not suf-
ficient to reduce the viraemia peak. Our aim is to keep the viral load approximately below 108
but for DENV-2 and DENV-3 it is difficult to achieve that even after applying 1011 DI particles.
The reason behind this is the higher rates of virus replication (β and π2) in DENV-2 and
DENV-3, as mentioned before. In the cases of DENV-1 and DENV-4, as soon as the DI parti-
cles start boosting, the viral load drops quickly, as the DI particles interfere in the virus replica-
tion. Very tiny persistent oscillations in the case of DENV-2 and DENV-3 in all the cell types
and viraemia also validates the same conclusions.
To examine the efficiency of the control experiment, we refer to the scatter plot in Fig 9
for the measured control expense (A) and the corresponding reduction in viraemia (R). For
DENV-1, DENV-3 and DENV-4, most of the models are in the left half of the figure (i.e.,
A� 103) while DENV-2 has many more models in the high A domain (i.e., A� 103). In most
of the cases for DENV-1, the reduction (R) is higher than the other serotypes at low expense of
control (A) and that makes the control for DENV-1 the most efficient. The present model pre-
dicts that large numbers of DI particles would be administered to DENV patients to have any
effect on viraemia as patients only become symptomatic and seek medical assistance at the
time of peak viraemia or soon after. The model also assumes that DI particles and wild type
viruses are of equal fitness when competing for replicative machinery within the host cell. If,
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however, DI particles are interfering with replication of wild type viruses by enhancing pro-
duction of interferon or some other mediator, then a single DI particle/genome may elicit a
response in the host cell that interferes with the replication of large number of wild type
viruses. In addition, there exists no specific metric that may provide room to define the effi-
ciency of the DI particles. A distribution of DI genomes with variability in their competitions
with the virus RNAs for the replication and packaging can be modelled to predict the efficiency
of the DI particles through successive passages. Although, existing models and experiments
with DI particles assume the efficiency of the DI particles is inversely proportional to their
nucleotide lengths [23], just the nucleotide lengths cannot decide on DI particle efficiency.
Shorter genome length may help DI particles in faster replication, but deletion mutations only
at the genes of non-structural proteins can increase the DI particles efficiency, which is a ran-
dom event. Hence, a single cell stochastic model with distribution of DI particles and their evo-
lutionary aspects may open a new avenue to explore DI particle efficiency.
Despite the availability of real clinical data for the admitted patients and experimental suc-
cess, the intra-host dengue virus dynamics is not explored well. As a consequence, the virus
transmission dynamics to mosquitoes is not clear. This paper explores the variability regime of
the intra-host DENV dynamics across a population of patients for the four DENV serotypes.
These POMs are able to predict the effective roles of the virus replication and subsequent
immune response to determine the within-host viraemia characteristics. For the same patients
population, a human to mosquito transmission model is underway. Those results may explore
the quantitative analysis of infected patients turned into infectious and their infectiousness in
terms of the transmission. Addition of minimal amount of defective particles leads to signifi-
cant reduction in the viraemia characteristics reflecting the potential anti-viral property to be
manifested in dengue control.
Supporting information
S1 Fig. An arbitrarily chosen model from the POM is simulated with and without the
‘death’ terms for the CD (δCD) and CV (δCV) cells in Eq 1. The effect of the ‘death’ terms on
the model are shown by the viraemia (V), defective interfering particles (D), and two early
infected (CD and CV) cells levels. The black lines represent the model without the ‘death’
terms, while the red lines show the model dynamics with the ‘death’ terms. These results
reflect that inclusion of the ‘death’ terms cannot contribute significantly to the model dynam-
ics except the stability of the CD cells.
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